Directory
>
Drew Fromkin
Drew Fromkin
Chief Executive Officer | Roivant Sciences
Belmar, New Jersey, United States
Drew Fromkin
Summary
Drew Fromkin is a seasoned executive with extensive leadership experience in the biotechnology and healthcare sectors. He has a proven track record of driving growth and creating shareholder value, notably leading Clinical Data, Inc. to a successful acquisition for $1.2 billion. With a strong background in corporate development, strategic partnerships, and product marketing, Drew has held key positions in both public and private companies, including as CEO of Tarveda Therapeutics and Proteovant Therapeutics. His expertise spans across M&A, business development, and team leadership, making him a well-rounded professional in the life sciences industry. Drew is also actively involved in board governance, serving as Chair of the compensation committee at Immunovant. His educational foundation in biology from Brandeis University complements his hands-on experience in transforming organizations and advancing innovative healthcare solutions.
Drew Fromkin
Work Experience
Chief Executive Officer at
Pulmovant, Inc.
July 2023 - Present
Vant Portfolio Operating Partner (Roivant Sciences) at
Roivant Sciences
January 2021 - Present
Director, Board Member at
Immunovant
October 2019 - Present
Chief Executive Officer, Protoevant Therapeutics at
Roivant Sciences
January 2021 - April 2023
President and Chief Executive Officer, Chairman at
Tarveda Therapeutics, Inc
March 2015 - September 2020
Business Consultant and Director at
Ajf Consulting
August 2012 - March 2015
President, CEO and Director at
Clinical Data
May 2006 - May 2011
Executive Vice President at
Clinical Data
October 2005 - May 2006
Consultant - Strategic Business Development at
Aetna Inc.
May 2004 - March 2005
President and CEO at
DoctorQuality, Inc.
October 2002 - December 2003
President and CEO at
Endo Surgical Devices Inc
January 2001 - August 2002
Vice President - Business Development (Corp. Dev. Function) at
Merck
January 1993 - January 2000
Director Marketing(HIT)/GM (Subsidiary) at
Health Information Technologies, Inc.
January 1988 - January 1993
Drew Fromkin
Education
January 1984 - January 1988
Frequently Asked Questions about Drew Fromkin
What is Drew Fromkin email address?
Drew Fromkin's primary email address is ********@tarveda.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Drew Fromkin work for?
Drew Fromkin is a Chief Executive Officer at Roivant Sciences.
Where Drew Fromkin graduated from?
Drew Fromkin holds a degree in Biology from Brandeis University.
How can I directly contact Drew Fromkin?
To contact Drew Fromkin directly, you can use the email address ********@tarveda.com. Complete contact information is available upon registration with Muraena.
Who is Drew Fromkin?
Drew Fromkin is a seasoned executive with extensive leadership experience in the biotechnology and healthcare sectors. He has a proven track record of driving growth and creating shareholder value, notably leading Clinical Data, Inc. to a successful acquisition for $1.2 billion. With a strong background in corporate development, strategic partnerships, and product marketing, Drew has held key positions in both public and private companies, including as CEO of Tarveda Therapeutics and Proteovant Therapeutics. His expertise spans across M&A, business development, and team leadership, making him a well-rounded professional in the life sciences industry. Drew is also actively involved in board governance, serving as Chair of the compensation committee at Immunovant. His educational foundation in biology from Brandeis University complements his hands-on experience in transforming organizations and advancing innovative healthcare solutions.
Drew`s contact details
********@tarveda.com
********@roivant.com
Colleagues
Chief Development Officer
Chief Communications Officer
Chief Financial Officer
Executive Director
VP, Special Projects, Office of CEO
Vice President, Head of CMC, Small Molecule Development
VP, Research
Board Member
Senior Vice President, Investments
Vice President, Head of CMC, Biologics and Gene Therapies